# A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

> **NCT00462761** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 76 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Leukemia
- Myelodysplastic Syndrome
- AML
- MDS

## Interventions

- **DRUG:** AC220

## Key facts

- **NCT ID:** NCT00462761
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-03
- **Final completion:** 2009-12
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2020-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00462761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00462761, "A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00462761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*